Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2018

View Archived Issues

Mutations mediate mantle cell lymphoma resistance

Rocket reports preclinical data on gene therapy RP-A501 for Danon disease

Fratricide-resistant, allo-tolerant "off-the-shelf" CAR-T cells for T-cell malignancies

Noncanonical activity of nuclear LDHA induced by ROS leads to HPV-induced cervical carcinogenesis

Novel LpxC inhibitors identified against Gram-negative bacteria by computational scaffold-hopping

Protagonist Therapeutics to begin clinical development of PN-10943 for IBD

Novus initiates phase I trial of OP-0201 for otitis media

Wayne State University, University of Zurich divulge apramycin derivatives

Wockhardt describes new antibacterials

Jivi approved in Europe for hemophilia A

Androgen receptor eliminators patented by Spg Therapeutics

Anti-inflammatory compositions presented by House Wellness Foods, House Foods Group

GlaxoSmithKline discovers sodium channel protein type 9 subunit alpha blockers

Blaze Bioscience initiates pivotal phase II/III study for of BLZ-100 and the Canvas Imaging System

Phase II trial opens in Congo to investigate multiple investigational Ebola therapies

FDA approves rituximab biosimilar Truxima to treat NHL

MedImmune presents new antibody-drug conjugates for cancer

New phase IIb trial investigates efficacy of male contraceptive gel

Xospata approved in U.S. for relapsed or refractory AML with FLT3 mutation

FDA approves Firdapse to treat Lambert-Eaton myasthenic syndrome

European Commission approves label extension for Kalydeco

EC grants approval to Delstrigo and Pifeltro for HIV-1 infection

European Commission approves Gilenya for children and adolescents with relapsing-remitting MS

Preclinical evaluation of next-generation retroviral vector with membrane-anchored IL-12

M-7824 demonstrates manageable safety and encouraging efficacy in rGBM

HMGA2 as potential new target for therapeutic strategies in medulloblastoma

Repurposing glioma exomes as novel strategy for multiantigenic antiglioma vaccination

Using cell free DNA from CSF provides less invasive technique to evaluate IDH1 mutation in glioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...